Brennan, Paul N. http://orcid.org/0000-0001-8368-1478
Elsharkawy, Ahmed M.
Kendall, Timothy J. http://orcid.org/0000-0002-4174-2786
Loomba, Rohit
Mann, Derek A. http://orcid.org/0000-0003-0950-243X
Fallowfield, Jonathan A. http://orcid.org/0000-0002-5741-1471
Article History
Accepted: 9 May 2023
First Online: 2 June 2023
Competing interests
: P.N.B. has received educational honoraria from Takeda. P.N.B. also served as a consultant and is employed by Resolution Therapeutics. J.A.F. serves as a consultant or advisory board member for Ipsen, Redx Pharma, River 2 Renal Corp., Stimuliver, Galecto Biotech, Resolution Therapeutics and Global Clinical Trial Partners. J.A.F. has received research funding from Genentech and Intercept Pharmaceuticals. T.J.K. serves as a consultant or received speaker fees from Resolution Therapeutics, Clinovate Health, Perspectum Diagnostics and Incyte Corporation. A.M.E. serves as a consultant or received speaker fees from GSK, Gilead and SOBI. D.A.M. is a director, major shareholder and salaried CSO of FibroFind Ltd, has received research funding from GSK and collaborates with AstraZeneca on novel treatments for advanced hepatocellular carcinoma. R.L. serves as a consultant to Aardvark Therapeutics, Altimmune, Anylam/Regeneron, Amgen, Arrowhead Pharmaceuticals, AstraZeneca, Bristol Myers Squibb, CohBar, Eli Lilly, Galmed, Gilead, Glympse bio, Hightide, Inipharma, Intercept, Inventiva, Ionis, Janssen Inc., Madrigal, Metacrine Inc., NGM Biopharmaceuticals, Novartis, Novo Nordisk, Merck, Pfizer, Sagimet, Theratechnologies, 89 bio, Terns Pharmaceuticals and Viking Therapeutics. In addition, R.L.’s institutions received research grants from Arrowhead Pharmaceuticals, AstraZeneca, Boehringer-Ingelheim, Bristol Myers Squibb, Eli Lilly, Galectin Therapeutics, Galmed Pharmaceuticals, Gilead, Intercept, Hanmi, Intercept, Inventiva, Ionis, Janssen, Madrigal Pharmaceuticals, Merck, NGM Biopharmaceuticals, Novo Nordisk, Merck, Pfizer, Sonic Incytes and Terns Pharmaceuticals. R.L. is also co-founder of LipoNexus Inc.
Free to read: This content has been made available to all.